Secukinumab Approved for Plaque Psoriasis in Children, Adolescents

Video

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

Related Videos
Related Content

FDA Delays UCB’s Bimekizumab Approval

September 20th 2023

The Cutaneous Connection: Diving Into the Aesthetics Industry

February 17th 2022

Dermoscopy Aids in Diagnosing Psoriasis Vulgaris and Nail Psoriasis

September 19th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

GRAPPA Continues Efforts to Advance Care for Patients With Plaque Psoriasis

September 15th 2023

Skin of Color Resources for Clinicians

September 15th 2023

FDA Delays UCB’s Bimekizumab Approval

September 20th 2023

The Cutaneous Connection: Diving Into the Aesthetics Industry

February 17th 2022

Dermoscopy Aids in Diagnosing Psoriasis Vulgaris and Nail Psoriasis

September 19th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

GRAPPA Continues Efforts to Advance Care for Patients With Plaque Psoriasis

September 15th 2023

Skin of Color Resources for Clinicians

September 15th 2023

FDA Delays UCB’s Bimekizumab Approval

September 20th 2023

The Cutaneous Connection: Diving Into the Aesthetics Industry

February 17th 2022

Dermoscopy Aids in Diagnosing Psoriasis Vulgaris and Nail Psoriasis

September 19th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

GRAPPA Continues Efforts to Advance Care for Patients With Plaque Psoriasis

September 15th 2023

Skin of Color Resources for Clinicians

September 15th 2023
© 2023 MJH Life Sciences

All rights reserved.